Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Laureen Noll

Child & Adolescent Psychiatry Simpsonville, SC Medical Doctor

NPI 1144271867 CMS profile 1050635

20 Powderhorn Rd, Simpsonville, SC 29681

Open in the dashboard

General payments

$1,931

112 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Laureen Noll of Simpsonville, SC is reported in the CMS Open Payments database as having received $1,931 across 112 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $256 13
2022 General $645 32
2021 General $400 24
2020 General $165 11
2019 General $465 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Laureen Noll
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Laureen Noll were reported at $0. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Laureen Noll Child & Adolescent Psychiatry median Middle half National median
2019 $465 $129 $42–$419 $163
2020 $165 $81 $28–$226 $114
2021 $400 $115 $31–$326 $132
2022 $645 $124 $40–$382 $149
2023 $256 $130 $45–$420 $160
2024 $0 $141 $42–$490 $164
2025 $0 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Sunovion Pharmaceuticals Inc. $447 28 payments
  2. Teva Pharmaceuticals USA, Inc. $243 11 payments
  3. ITI, Inc. $216 11 payments
  4. Alkermes, Inc. $214 12 payments
  5. Otsuka America Pharmaceutical, Inc. $188 11 payments
  6. Janssen Pharmaceuticals, Inc $175 11 payments
  7. Neurocrine Biosciences, Inc. $125 7 payments
  8. Supernus Pharmaceuticals, Inc. $61 4 payments
  9. Vanda Pharmaceuticals Inc. $59 3 payments
  10. Shire North American Group Inc $47 4 payments
  11. Other $155 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,931 112 payments
Products named General payments · program years 2019–2023
  1. LATUDA $447 28 payments
  2. AUSTEDO $221 10 payments
  3. CAPLYTA $216 11 payments
  4. ARISTADA INITIO $197 11 payments
  5. ARISTADA Cns $197 11 payments
  6. ARISTADA Cns $197 11 payments
  7. INVEGA SUSTENNA $161 10 payments
  8. INVEGA TRINZA $161 10 payments
  9. LYBALVI Cns $133 7 payments
  10. LYBALVI Cns $133 7 payments
  11. Other $980 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

112 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record